Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Project description

Next generation allergen therapy

Allergies result from a hypersensitivity of the immune system – a condition affecting more than a billion people, causing significant social and economic burden. Prevailing treatments mainly include medication to alleviate symptoms and allergen immunotherapy (AIT), which requires as much as near-half a decade to train the immune system to tolerate allergens. AllergyVAX provides a platform technology that creates modified hypoallergens for AIT. These hypoallergens are expected to significantly shorten treatment time – from dozens of injections over a minimum three-year-period to 3-6 injections over just a few months. Pre-clinical testing has already shown a 100-fold drop in histamine release compared to natural allergens.

Objective

Allergy is a rapidly increasing, global problem that already affects 1 billion people and causes significant social and economic burden. In Europe, allergic rhinitis and asthma cause more than 100 million missed work and school days per year. Allergy is usually managed by avoiding the allergen or by medication that temporarily alleviates the symptoms. The only disease-modifying treatment available to date is allergen immunotherapy (AIT) where long-term symptom relief is achieved by training the immune system to tolerate allergens. However, typical AIT takes 3-5 years, involves monthly injections or daily drops/tablets and has the risk of serious allergic reactions during treatment. Thus, the popularity of AIT is still relatively low compared to symptomatic drugs. We have developed a platform technology for creating modified hypoallergens to be used in AIT. It is based on making small, highly targeted modifications to allergen proteins that reduce their ability to trigger allergic reactions during treatment without compromising their efficacy in building tolerance to natural allergens. With these modified hypoallergens, we expect to shorten the injectable AIT treatment from dozens of injections over 3 years to just 3-6 injections over a few months. From the clinically important major birch pollen allergen Bet v 1 we have created rBet v 1 dm hypoallergen. In preclinical tests it has shown 100-fold reduction in histamine release compared to natural allergens and induced similar immunological responses in mice that are desired in human AIT. In the AllergyVAX project we will test rBet v 1 dm for maximum tolerated dose and immunogenicity in allergic patients in a phase I/IIa clinical trial. The project will facilitate seamless transition to phase IIb-III clinical development, establishing a basis for product launch with selected partners and advancing other hypoallergens in the pipeline, including product candidates for grass pollen, dog, horse and peanut allergies.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

DESENTUM OY
Net EU contribution
€ 1 885 000,00
Address
C/0 PEKKA MATTILA PERUSTIE 13 A 7
00330 HELSINKI
Finland
SME
Yes
Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 684 750,00